Key result
DOACs are a safe alternative to LMWH and UFH for extended postoperative VTE prophylaxis in select patients with gynecologic cancer, potentially improving compliance and cost savings.
Why the study?
Venous thromboembolism is a common cause of morbidity and mortality postoperatively in gynecologic oncology, and direct oral anticoagulants have emerged as an alternative to guideline-recommended injectable heparin prophylaxis.
Do direct oral anticoagulants (DOACs) provide safe and effective postoperative VTE prophylaxis with improved compliance and patient experience compared to LMWH or UFH in patients with gynecologic malignancies?
Do direct oral anticoagulants (DOACs) provide safe and effective postoperative VTE prophylaxis with improved compliance and patient experience compared to LMWH or UFH in patients with gynecologic malignancies?
DOACs represent a safe, cost-effective, and patient-friendly alternative to traditional injectable heparins for extended postoperative VTE prophylaxis in gynecologic oncology patients.
Answers are grounded in this paper and cite their sources.
May support DOAC consideration for extended VTE prophylaxis post-laparotomy; leaves open need for confirmatory RCTs.
• VTE is a common cause of morbidity and mortality in gynecologic oncology patients. • DOACs have been established as safe compared to LMWH and UFH for postoperative VTE prophylaxis. • DOAC use for postoperative anticoagulation leads to improved compliance, patient experience, and cost-effectiveness. • Gynecologic Oncologists should consider DOACs for extended postoperative VTE prophylaxis in patients after laparotomy. Venous thromboembolism (VTE) is a common cause of morbidity and mortality in gynecologic oncology patients with an increased risk in the postoperative period. Historically, international guidelines have recommended 28 days of low molecular weight heparin (LMWH) or unfractionated heparin (UFH) for extended VTE prophylaxis after major abdominal and pelvic surgery for gynecologic malignancies. Direct oral anticoagulants (DOACs) have emerged as an attractive alternative to injectable anticoagulants. This quality mini-review evaluated the literature around the use of DOACs for postoperative VTE prophylaxis after surgery for gynecologic cancer. Overall, the reviewed literature supports the use of DOACs in select patients within this population which may lead to an improved patient experience, higher rates of treatment compliance, and increased cost savings.
No takes yet. Share an insight, caveat, or question.
Ketch et al. (2024) conducted a review in Gynecologic malignancies. Direct oral anticoagulants (DOACs) vs. Low molecular weight heparin (LMWH) or unfractionated heparin (UFH) was evaluated on Safety, compliance, patient experience, and cost-effectiveness of VTE prophylaxis. DOACs are a safe alternative to LMWH and UFH for extended postoperative VTE prophylaxis in select patients with gynecologic cancer, potentially improving compliance and cost savings.
Synapse has enriched 10 related papers. Consider them for comparative context: